Meeting
2020 ASCO Virtual Scientific Program
Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes.
Presenter
Reva K Basho, MD
Cedars-Sinai Medical Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 561)
DOI
10.1200/JCO.2020.38.15_suppl.561
Abstract #
561
Poster Bd #
53
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2020 ASCO Virtual Scientific Program
Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide.
Speaker: Bora Lim, MD
Speaker: Allison Elizabeth Garda, MD
Videos & Slides
2023 ASCO Annual Meeting
Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.
Speaker: Shane R Stecklein, MD, PhD
Videos & Slides
2023 ASCO Annual Meeting
Neoadjuvant Therapy in Triple-Negative Breast Cancer: Where We Are and What's Next?
Speaker: Erica Michelle Stringer-Reasor, MD